INDV Q4 2022 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$242M+8.5% YoY

Gross Profit

$198M81.8% margin

Operating Income

-$258M-106.6% margin

Net Income

-$183M-75.6% margin

EPS (Diluted)

$-1.38

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.7B

Stockholders' Equity

$51M

Cash & Equivalents

$778M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$242M	$223M	+8.5%
Gross Profit	$198M	$184M	+7.6%
Operating Income	-$258M	$45M	-673.3%
Net Income	-$183M	$36M	-608.3%